Cardiac function in women receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer.
Jamal ZekriHaleem RasoolSyed Azhar J RizviHany EldeebAboelkhair Al-GahmiKamel FaragAyman RasmyPublished in: Women's health (London, England) (2023)
In this cohort describing our limited initial experience, dual anti-Her2 antibodies (Trastuzumab and Pertuzumab) combined with chemotherapy is effective and not associated with significant cardiac toxicity when the left ventricular ejection fraction is measured every 3 months. This may suggest that previous concerns about cardiotoxicity may have been overemphasized. Further studies investigating less frequent left ventricular ejection fraction monitoring may be warranted.
Keyphrases
- ejection fraction
- aortic stenosis
- left ventricular
- epidermal growth factor receptor
- metastatic breast cancer
- tyrosine kinase
- hypertrophic cardiomyopathy
- locally advanced
- acute myocardial infarction
- heart failure
- left atrial
- cardiac resynchronization therapy
- mitral valve
- polycystic ovary syndrome
- oxidative stress
- breast cancer risk
- type diabetes
- transcatheter aortic valve replacement
- acute coronary syndrome
- aortic valve
- skeletal muscle
- metabolic syndrome
- percutaneous coronary intervention
- insulin resistance
- atrial fibrillation